PCVX

Vaxcyte Inc

PCVX, USA

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

https://vaxcyte.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PCVX
stock
PCVX

How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors Yahoo Finance

Read more →
PCVX
stock
PCVX

Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$92

Analyst Picks

Strong Buy

9

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.10

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-7.36 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-6.71 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.10

Low 1

High 0.3

Investors

* Institutions hold a combined 115.08% of the total shares of Vaxcyte Inc

1.

HHG PLC

(11.3164%)

since

2025/06/30

2.

FMR Inc

(9.3597%)

since

2025/06/30

3.

Vanguard Group Inc

(9.2411%)

since

2025/06/30

4.

RA Capital Management, LLC

(9.2171%)

since

2025/06/30

5.

BlackRock Inc

(8.1975%)

since

2025/06/30

6.

T. Rowe Price Investment Management,Inc.

(4.6225%)

since

2025/06/30

7.

Wellington Management Company LLP

(3.8166%)

since

2025/06/30

8.

State Street Corp

(3.8069%)

since

2025/06/30

9.

Capital Research Global Investors

(3.6756%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.972%)

since

2025/07/31

11.

Paradigm Biocapital Advisors LP

(2.598%)

since

2025/06/30

12.

T. Rowe Price Associates, Inc.

(2.442%)

since

2025/06/30

13.

D. E. Shaw & Co LP

(2.379%)

since

2025/06/30

14.

Kynam Capital Management, LP

(2.366%)

since

2025/06/30

15.

Westfield Capital Management Company, L.P.

(2.3639%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(2.3299%)

since

2025/08/31

17.

Geode Capital Management, LLC

(2.3194%)

since

2025/06/30

18.

Vanguard Small Cap Index

(2.2922%)

since

2025/07/31

19.

Vanguard Health Care Inv

(2.183%)

since

2025/06/30

20.

Janus Henderson Enterprise D

(2.0355%)

since

2025/06/30

21.

Janus Inst Mid Cap Growth CF

(2.0355%)

since

2025/06/30

22.

Janus Concentrated Growth CF

(1.6608%)

since

2025/06/30

23.

Janus Henderson Forty S

(1.6608%)

since

2025/06/30

24.

Deep Track Capital, LP

(1.6561%)

since

2025/06/30

25.

SPDR® S&P Biotech ETF

(1.5496%)

since

2025/08/31

26.

T. Rowe Price Mid-Cap Growth

(1.3455%)

since

2025/07/31

27.

American Funds New Economy A

(1.3372%)

since

2025/06/30

28.

Capital Group New Economy Comp

(1.3372%)

since

2025/06/30

29.

Vanguard Small Cap Growth Index Inv

(1.2791%)

since

2025/07/31

30.

T. Rowe Price US Mid-Cap Growth Equity

(1.2324%)

since

2025/06/30

31.

Fidelity Advisor Growth Opps M

(1.2046%)

since

2025/07/31

32.

American Funds SMALLCAP World A

(1.1466%)

since

2025/06/30

33.

Charles Schwab Investment Management Inc

(1.092%)

since

2025/06/30

34.

Jennison Associates LLC

(1.0778%)

since

2025/06/30

35.

UBS Group AG

(1.0636%)

since

2025/06/30

36.

Maverick Capital Ltd

(1.0095%)

since

2025/06/30

37.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9818%)

since

2025/07/31

38.

Fidelity Small Cap Index

(0.9726%)

since

2025/06/30

39.

American Funds Growth Fund of Amer A

(0.9513%)

since

2025/06/30

40.

Capital Group Growth Fnd of Amer Comp

(0.9513%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.47

Latest Release

Date

2025-09-30

EPS Actual

-1.56

EPS Estimate

-1.24

EPS Difference

-0.32

Surprise Percent

-25.8065%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.